Different patterns of epstein-barr virus latency in endemic Burkitt Lymphoma (BL) lead to distinct variants within the BL-associated gene expression signature

Journal of Virology

Volumn 87, Issue 5, 2013, Pages 2882-2894

  Kelly, Gemma L ^a,e   Wei Wenbin, W ^a   Thomas, Wendy ^a   Croom Carter, Deborah ^a   Stylianou, Julianna ^a   Woodman, Ciaran ^a   Bell, Andrew I ^a   Rickinson, Alan B ^a   Rasaiyaah, Jane ^b   Kellam, Paul ^b,d   Kohler, Christian ^c   Spang, Rainer ^c  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF REGENSBURG   (Germany)

^d WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^e WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

B LYMPHOCYTE INDUCED MATURATION PROTEIN 1; BHRF1 PROTEIN; EPSTEIN BARR VIRUS ANTIGEN; EPSTEIN BARR VIRUS ANTIGEN 1; EPSTEIN BARR VIRUS ANTIGEN 2; EPSTEIN BARR VIRUS ANTIGEN 3A; EPSTEIN BARR VIRUS ANTIGEN 3B; EPSTEIN BARR VIRUS ANTIGEN 3C; INTERFERON REGULATORY FACTOR 4; PROTEIN BCL 6; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ANTIGEN EXPRESSION; BLIMP1 GENE; BURKITT LYMPHOMA; CONTROLLED STUDY; DOWN REGULATION; ENDEMIC DISEASE; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS ANTIGEN 2 GENE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GERMINAL CENTER; HUMAN; HUMAN CELL; IRF4 GENE; LARGE CELL LYMPHOMA; LYMPHOMA CELL LINE; MARKER GENE; PRIORITY JOURNAL; REVIEW; UPREGULATION; VIRUS GENE; VIRUS GENOME; VIRUS LATENCY;

ANTIGENS, VIRAL; BURKITT LYMPHOMA; CELL LINE, TUMOR; DNA-BINDING PROTEINS; DOWN-REGULATION; EPSTEIN-BARR VIRUS NUCLEAR ANTIGENS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, VIRAL; HERPESVIRUS 4, HUMAN; HUMANS; INTERFERON REGULATORY FACTORS; REPRESSOR PROTEINS; TRANSCRIPTOME; UP-REGULATION; VIRAL PROTEINS; VIRUS LATENCY;

EID: 84874744553     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.03003-12     Document Type: Review

References (60)

1. Bornkamm GW. 2009. Epstein-Barr virus and the pathogenesis of Burkitt's lymphoma: more questions than answers. Int. J. Cancer 124: 1745-1755.
2. Magrath I. 1990. The pathogenesis of Burkitt's lymphoma. Adv. Cancer Res. 55:133-270.
3. Gregory CD, Tursz T, Edwards CF, Tetaud C, Talbot M, Caillou B, Rickinson AB, Lipinski M. 1987. Identification of a subset of normal B cells with a Burkitt's lymphoma (BL)-like phenotype. J. Immunol. 139: 313-318.
4. Dalla-Favera R, Bregni M, Erikson J, Patterson D, Gallo RC, Croce CM. 1982. Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. Proc. Natl. Acad. Sci. U. S. A. 79:7824 -7827.
5. Taub R, Kirsch I, Morton C, Lenoir G, Swan D, Tronick S, Aaronson S, Leder P. 1982. Translocation of the c-myc gene into the immunoglobulin heavy chain locus in human Burkitt lymphoma and murine plasmacytoma cells. Proc. Natl. Acad. Sci. U. S. A. 79:7837-7841.
6. Schmitz R, Young RM, Ceribelli M, Jhavar S, Xiao W, Zhang M, Wright G, Shaffer AL, Hodson DJ, Buras E, Liu X, Powell J, Yang Y, Xu W, Zhao H, Kohlhammer H, Rosenwald A, Kluin P, Muller-Hermelink HK, Ott G, Gascoyne RD, Connors JM, Rimsza LM, Campo E, Jaffe ES, Delabie J, Smeland EB, Ogwang MD, Reynolds SJ, Fisher RI, Braziel RM, Tubbs RR, Cook JR, Weisenburger DD, Chan WC, Pittaluga S, Wilson W, Waldmann TA, Rowe M, Mbulaiteye SM, Rickinson AB, Staudt LM. 2012. Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature 490:116 -120.
7. Richter J, Schlesner M, Hoffmann S, Kreuz M, Leich E, Burkhardt B, Rosolowski M, Ammerpohl O, Wagener R, Bernhart SH, Lenze D, Szczepanowski M, Paulsen M, Lipinski S, Russell RB, Adam-Klages S, Apic G, Claviez A, Hasenclever D, Hovestadt V, Hornig N, Korbel JO, Kube D, Langenberger D, Lawerenz C, Lisfeld J, Meyer K, Picelli S, Pischimarov J, Radlwimmer B, Rausch T, Rohde M, Schilhabel M, Scholtysik R, Spang R, Trautmann H, Zenz T, Borkhardt A, Drexler HG, Moller P, Macleod RA, Pott C, Schreiber S, Trumper L, Loeffler M, Stadler PF, Lichter P, Eils R, Kuppers R, Hummel M, Klapper W, Rosenstiel P, Rosenwald A, Brors B, Siebert R. 2012. Recurrent mutation of the ID3 gene in Burkitt lymphoma identified by integrated genome, exome and transcriptome sequencing. Nat. Genet. 44:1316 -1320.
8. Polack A, Hortnagel K, Pajic A, Christoph B, Baier B, Falk M, Mautner J, Geltinger C, Bornkamm GW, Kempkes B. 1996. c-myc activation renders proliferation of Epstein-Barr virus (EBV)-transformed cells independent of EBV nuclear antigen 2 and latent membrane protein 1. Proc. Natl. Acad. Sci. U. S. A. 93:10411-10416.
9. Kovalchuk AL, Qi CF, Torrey TA, Taddesse-Heath L, Feigenbaum L, Park SS, Gerbitz A, Klobeck G, Hoertnagel K, Polack A, Bornkamm GW, Janz S, Morse HC, III. 2000. Burkitt lymphoma in the mouse. J. Exp. Med. 192:1183-1190.
10. Zhu D, Qi CF, Morse HC, III, Janz S, Stevenson FK. 2005. Deregulated expression of the Myc cellular oncogene drives development of mouse " Burkitt-like" lymphomas from naive B cells. Blood 105:2135-2137.
11. Salaverria I, Siebert R. 2011. The gray zone between Burkitt's lymphoma and diffuse large B-cell lymphoma from a genetics perspective. J. Clin. Oncol. 29:1835-1843.
12. Hummel M, Bentink S, Berger H, Klapper W, Wessendorf S, Barth TF, Bernd HW, Cogliatti SB, Dierlamm J, Feller AC, Hansmann ML, Haralambieva E, Harder L, Hasenclever D, Kuhn M, Lenze D, Lichter P, Martin-Subero JI, Moller P, Muller-Hermelink HK, Ott G, Parwaresch RM, Pott C, Rosenwald A, Rosolowski M, Schwaenen C, Sturzenhofecker B, Szczepanowski M, Trautmann H, Wacker HH, Spang R, Loeffler M, Trumper L, Stein H, Siebert R. 2006. A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. N. Engl. J. Med. 354:2419 -2430.
13. Dave SS, Fu K, Wright GW, Lam LT, Kluin P, Boerma EJ, Greiner TC, Weisenburger DD, Rosenwald A, Ott G, Muller-Hermelink HK, Gascoyne RD, Delabie J, Rimsza LM, Braziel RM, Grogan TM, Campo E, Jaffe ES, Dave BJ, Sanger W, Bast M, Vose JM, Armitage JO, Connors JM, Smeland EB, Kvaloy S, Holte H, Fisher RI, Miller TP, Montserrat E, Wilson WH, Bahl M, Zhao H, Yang L, Powell J, Simon R, Chan WC, Staudt LM. 2006. Molecular diagnosis of Burkitt's lymphoma. N. Engl. J. Med. 354:2431-2442.
14. Piccaluga PP, De Falco G, Kustagi M, Gazzola A, Agostinelli C, Tripodo C, Leucci E, Onnis A, Astolfi A, Sapienza MR, Bellan C, Lazzi S, Tumwine L, Mawanda M, Ogwang M, Calbi V, Formica S, Califano A, Pileri SA, Leoncini L. 2011. Gene expression analysis uncovers similarity and differences among Burkitt lymphoma subtypes. Blood 117:3596- 3608.
15. Kelly GL, Rickinson AB. 2007. Burkitt lymphoma: revisiting the pathogenesis of a virus-associated malignancy. Hematology Am. Soc. Hematol. Educ. Program 2007:277-284.
16. Rickinson AB, Kieff E. 2007. Epstein-Barr virus, p 2655-2700. In Knipe DM, Howley PM, Griffin DE, Lamb RA, Martin MA, Roizman B, Straus SE (ed), Fields virology, 5th ed, vol II. Lippincott Williams & Wilkins, Philadelphia, PA.
17. Rowe DT, Rowe M, Evan GI, Wallace LE, Farrell PJ, Rickinson AB. 1986. Restricted expression of EBV latent genes and T-lymphocytedetected membrane antigen in Burkitt's lymphoma cells. EMBO J. 5:2599 -2607.
18. Rowe M, Rowe DT, Gregory CD, Young LS, Farrell PJ, Rupani H, Rickinson AB. 1987. Differences in B cell growth phenotype reflect novel patterns of Epstein-Barr virus latent gene expression in Burkitt's lymphoma cells. EMBO J. 6:2743-2751.
19. Rooney CM, Gregory CD, Rowe M, Finerty S, Edwards C, Rupani H, Rickinson AB. 1986. Endemic Burkitt's lymphoma: phenotypic analysis of tumor biopsy cells and of derived tumor cell lines. J. Natl. Cancer Inst. 77:681- 687.
20. Sample J, Brooks L, Sample C, Young L, Rowe M, Gregory C, Rickinson A, Kieff E. 1991. Restricted Epstein-Barr virus protein expression in Burkitt lymphoma is due to a different Epstein-Barr nuclear antigen 1 transcriptional initiation site. Proc. Natl. Acad. Sci. U. S. A. 88:6343- 6347.
21. Schaefer BC, Woisetschlaeger M, Strominger JL, Speck SH. 1991. Exclusive expression of Epstein-Barr virus nuclear antigen 1 in Burkitt lymphoma arises from a third promoter, distinct from the promoters used in latently infected lymphocytes. Proc. Natl. Acad. Sci. U. S. A. 88:6550- 6554.
22. Tao Q, Robertson KD, Manns A, Hildesheim A, Ambinder RF. 1998. Epstein-Barr virus (EBV) in endemic Burkitt's lymphoma: molecular analysis of primary tumor tissue. Blood 91:1373-1381.
23. Kelly G, Bell A, Rickinson A. 2002. Epstein-Barr virus-associated Burkitt lymphomagenesis selects for downregulation of the nuclear antigen EBNA2. Nat. Med. 8:1098 -1104.
24. Kelly GL, Long HM, Stylianou J, Thomas WA, Leese A, Bell AI, Bornkamm GW, Mautner J, Rickinson AB, Rowe M. 2009. An Epstein- Barr virus anti-apoptotic protein constitutively expressed in transformed cells and implicated in Burkitt lymphomagenesis: the Wp/BHRF1 link. PLoS Pathog. 5:e1000341. doi:10.1371/journal.ppat.1000341.
25. Kelly GL, Milner AE, Tierney RJ, Croom-Carter DS, Altmann M, Hammerschmidt W, Bell AI, Rickinson AB. 2005. Epstein-Barr virus nuclear antigen 2 (EBNA2) gene deletion is consistently linked with EBNA3A, -3B, and -3C expression in Burkitt's lymphoma cells and with increased resistance to apoptosis. J. Virol. 79:10709 -10717.
26. Kelly GL, Milner AE, Baldwin GS, Bell AI, Rickinson AB. 2006. Three restricted forms of Epstein-Barr virus latency counteracting apoptosis in c-myc-expressing Burkitt lymphoma cells. Proc. Natl. Acad. Sci. U. S. A. 103:14935-14940.
27. Calender A, Billaud M, Aubry JP, Banchereau J, Vuillaume M, Lenoir GM. 1987. Epstein-Barr virus (EBV) induces expression of B-cell activation markers on in vitro infection of EBV-negative B-lymphoma cells. Proc. Natl. Acad. Sci. U. S. A. 84:8060-8064.
28. Habeshaw G, Yao QY, Bell AI, Morton D, Rickinson AB. 1999. Epstein- Barr virus nuclear antigen 1 sequences in endemic and sporadic Burkitt's lymphoma reflect virus strains prevalent in different geographic areas. J. Virol. 73:965-975.
29. Altmann M, Hammerschmidt W. 2005. Epstein-Barr virus provides a new paradigm: a requirement for the immediate inhibition of apoptosis. PLoS Biol. 3:e404. doi:10.1371/journal.pbio.0030404.
30. Tierney R, Nagra J, Hutchings I, Shannon-Lowe C, Altmann M, Hammerschmidt W, Rickinson A, Bell A. 2007. Epstein-Barr virus exploits BSAP/Pax5 to achieve the B-cell specificity of its growth-transforming program. J. Virol. 81:10092-10100.
31. Grasser FA, Murray PG, Kremmer E, Klein K, Remberger K, Feiden W, Reynolds G, Niedobitek G, Young LS, Mueller-Lantzsch N. 1994. Monoclonal antibodies directed against the Epstein-Barr virus-encoded nuclear antigen 1 (EBNA1): immunohistologic detection of EBNA1 in the malignant cells of Hodgkin's disease. Blood 84:3792-3798.
32. Maunders MJ, Petti L, Rowe M. 1994. Precipitation of the Epstein-Barr virus protein EBNA-2 by an EBNA-3C-specific monoclonal antibody. J. Gen. Virol. 75:769 -778.
33. Rowe M, Evans HS, Young LS, Hennessy K, Kieff E, Rickinson AB. 1987. Monoclonal antibodies to the latent membrane protein of Epstein- Barr virus reveal heterogeneity of the protein and inducible expression in virus-transformed cells. J. Gen. Virol. 68:1575-1586.
34. Lopes AR, Kellam P, Das A, Dunn C, Kwan A, Turner J, Peppa D, Gilson RJ, Gehring A, Bertoletti A, Maini MK. 2008. Bim-mediated deletion of antigen-specific CD8 T cells in patients unable to control HBV infection. J. Clin. Invest. 118:1835-1845.
35. Ritchie ME, Silver J, Oshlack A, Holmes M, Diyagama D, Holloway A, Smyth GK. 2007. A comparison of background correction methods for two-colour microarrays. Bioinformatics 23:2700 -2707.
36. Smyth GK, Speed T. 2003. Normalization of cDNA microarray data. Methods 31:265-273.
37. Saeed AI, Sharov V, White J, Li J, Liang W, Bhagabati N, Braisted J, Klapa M, Currier T, Thiagarajan M, Sturn A, Snuffin M, Rezantsev A, Popov D, Ryltsov A, Kostukovich E, Borisovsky I, Liu Z, Vinsavich A, Trush V, Quackenbush J. 2003. TM4: a free, open-source system for microarray data management and analysis. Biotechniques 34:374 -378.
38. Saldanha AJ. 2004. Java Treeview-extensible visualization of microarray data. Bioinformatics 20:3246 -3248.
39. Storey JD, Tibshirani R. 2003. Statistical methods for identifying differentially expressed genes in DNA microarrays. Methods Mol. Biol. 224: 149-157.
40. Tusher VG, Tibshirani R, Chu G. 2001. Significance analysis of microarrays applied to the ionizing radiation response. Proc. Natl. Acad. Sci. U. S. A. 98:5116 -5121.
41. Bolstad BM, Irizarry RA, Astrand M, Speed TP. 2003. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 19:185-193.
42. Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, Speed TP. 2003. Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res. 31:e15. doi:10.1093/nar/gng015.
43. Bentink S, Wessendorf S, Schwaenen C, Rosolowski M, Klapper W, Rosenwald A, Ott G, Banham AH, Berger H, Feller AC, Hansmann ML, Hasenclever D, Hummel M, Lenze D, Moller P, Stuerzenhofecker B, Loeffler M, Truemper L, Stein H, Siebert R, Spang R. 2008. Pathway activation patterns in diffuse large B-cell lymphomas. Leukemia 22:1746- 1754.
44. Beier CP, Kumar P, Meyer K, Leukel P, Bruttel V, Aschenbrenner I, Riemenschneider MJ, Fragoulis A, Rummele P, Lamszus K, Schulz JB, Weis J, Bogdahn U, Wischhusen J, Hau P, Spang R, Beier D. 2012. The cancer stem cell subtype determines immune infiltration of glioblastoma. Stem Cells Dev. 21:2735-2761.
45. Gregory CD, Rowe M, Rickinson AB. 1990. Different Epstein-Barr virus- B cell interactions in phenotypically distinct clones of a Burkitt's lymphoma cell line. J. Gen. Virol. 71:1481-1495.
46. Pearson GR, Luka J, Petti L, Sample J, Birkenbach M, Braun D, Kieff E. 1987. Identification of an Epstein-Barr virus early gene encoding a second component of the restricted early antigen complex. Virology 160:151-161.
47. Faumont N, Durand-Panteix S, Schlee M, Gromminger S, Schuhmacher M, Holzel M, Laux G, Mailhammer R, Rosenwald A, Staudt LM, Bornkamm GW, Feuillard J. 2009. c-Myc and Rel/NF-kappaB are the two master transcriptional systems activated in the latency III program of Epstein- Barr virus-immortalized B cells. J. Virol. 83:5014 -5027.
48. Maier S, Staffler G, Hartmann A, Hock J, Henning K, Grabusic K, Mailhammer R, Hoffmann R, Wilmanns M, Lang R, Mages J, Kempkes B. 2006. Cellular target genes of Epstein-Barr virus nuclear antigen 2. J. Virol. 80:9761-9771.
49. Spender LC, Cornish GH, Sullivan A, Farrell PJ. 2002. Expression of transcription factor AML-2 (RUNX3, CBF(alpha)-3) is induced by Epstein- Barr virus EBNA-2 and correlates with the B-cell activation phenotype. J. Virol. 76:4919-4927.
50. Vockerodt M, Morgan SL, Kuo M, Wei W, Chukwuma MB, Arrand JR, Kube D, Gordon J, Young LS, Woodman CB, Murray PG. 2008. The Epstein-Barr virus oncoprotein, latent membrane protein-1, reprograms germinal centre B cells towards a Hodgkin's Reed-Sternberg-like phenotype. J. Pathol. 216:83-92.
51. Dennis G, Jr, Sherman BT, Hosack DA, Yang J, Gao W, Lane HC, Lempicki RA. 2003. DAVID: database for annotation, visualization, and integrated discovery. Genome Biol. 4:P3. doi:10.1186/gb-2003-4-5-p3.
52. Brune V, Tiacci E, Pfeil I, Doring C, Eckerle S, van Noesel CJ, Klapper W, Falini B, von Heydebreck A, Metzler D, Brauninger A, Hansmann ML, Kuppers R. 2008. Origin and pathogenesis of nodular lymphocytepredominant Hodgkin lymphoma as revealed by global gene expression analysis. J. Exp. Med. 205:2251-2268.
53. Carter KL, Cahir-McFarland E, Kieff E. 2002. Epstein-Barr virusinduced changes in B-lymphocyte gene expression. J. Virol. 76:10427- 10436.
54. Zhao B, Maruo S, Cooper A, Chase MR, Johannsen E, Kieff E, Cahir-McFarland E. 2006. RNAs induced by Epstein-Barr virus nuclear antigen 2 in lymphoblastoid cell lines. Proc. Natl. Acad. Sci. U. S. A. 103:1900-1905.
55. Schlee M, Krug T, Gires O, Zeidler R, Hammerschmidt W, Mailhammer R, Laux G, Sauer G, Lovric J, Bornkamm GW. 2004. Identification of Epstein-Barr virus (EBV) nuclear antigen 2 (EBNA2) target proteins by proteome analysis: activation of EBNA2 in conditionally immortalized B cells reflects early events after infection of primary B cells by EBV. J. Virol. 78:3941-3952.
56. Cahir McFarland ED, Izumi KM, Mosialos G. 1999. Epstein-Barr virus transformation: involvement of latent membrane protein 1-mediated activation of NF-kappaB. Oncogene 18:6959-6964.
57. Amoroso R, Fitzsimmons L, Thomas WA, Kelly GL, Rowe M, Bell AI. 2011. Quantitative studies of Epstein-Barr virus-encoded microRNAs provide novel insights into their regulation. J. Virol. 85:996 -1010.
58. White RE, Groves IJ, Turro E, Yee J, Kremmer E, Allday MJ. 2010. Extensive co-operation between the Epstein-Barr virus EBNA3 proteins in the manipulation of host gene expression and epigenetic chromatin modification. PLoS One 5:e13979. doi:10.1371/journal.pone.0013979.
59. Anderton E, Yee J, Smith P, Crook T, White RE, Allday MJ. 2008. Two Epstein-Barr virus (EBV) oncoproteins cooperate to repress expression of the proapoptotic tumour-suppressor Bim: clues to the pathogenesis of Burkitt's lymphoma. Oncogene 27:421-433.
60. Yee J, White RE, Anderton E, Allday MJ. 2011. Latent Epstein-Barr virus can inhibit apoptosis in B cells by blocking the induction of NOXA expression. PLoS One 6:e28506. doi:10.1371/journal.pone.0028506.